Progress in the field of noninvasive diagnostics for colorectal cancer: a systematic review for the accuracy of blood-based biomarkers for detection of advanced pre-cancerous lesions

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca A Cancer J Clinicians. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Nguyen LH, Goel A, Chung DC. Pathways of colorectal carcinogenesis. Gastroenterology. 2020;158(2):291–302. doi: 10.1053/j.gastro.2019.08.059
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: implications for diagnosis and therapy (review). Oncol Lett. 2018;16(1):9–18.
   PubMed Web of Science ®Google Scholar
• Brenner H, Hoffmeister M, Stegmaier C, et al. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut. 2007;56(11):1585–9.
   PubMed Web of Science ®Google Scholar
• Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One million Taiwanese screening program. Cancer. 2015;121(18):3221–9.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen G, Li Z, et al. Colonoscopic screening is associated with reduced colorectal cancer incidence and mortality: a systematic review and meta-analysis. J Cancer. 2020;11(20):5953–5970.
   PubMed Web of Science ®Google Scholar
• Pickhardt PJ, Hassan C, Halligan S, et al. Colorectal cancer: CT colonography and colonoscopy for detection–systematic review and meta-analysis. Radiology. 2011;259(2):393–405.
   PubMed Web of Science ®Google Scholar
• McFerran E, O’Mahony JF, Naber S, et al. Colorectal cancer screening within colonoscopy capacity constraints: can FIT-Based programs save more lives by trading off more sensitive test cutoffs against longer screening intervals? MDM Policy Pract. 2022;7(1):23814683221097064.
   Google Scholar
• Kim SY, Kim HS, Park HJ. Adverse events related to colonoscopy: global trends and future challenges. World J Gastroenterol. 2019;25(2):190–204. doi: 10.3748/wjg.v25.i2.190
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Gruber RN, Stump TE, et al. Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced adenomatous polyps. Ann internal med. 2019;170(5):319–329.
   PubMed Web of Science ®Google Scholar
• Cock C, Anwar S, Byrne SE, et al. Low sensitivity of fecal immunochemical tests and blood-based markers of DNA hypermethylation for detection of sessile serrated adenomas/polyps. Dig Dis Sci. 2019;64(9):2555–2562.
   PubMed Web of Science ®Google Scholar
• Chang LC, Shun CT, Hsu WF, et al. Fecal immunochemical test detects sessile serrated adenomas and polyps with a low level of sensitivity. Clin Gastroenterol Hepatol. 2017;15(6):872–879.e1.
   PubMed Web of Science ®Google Scholar
• Heigh RI, Yab TC, Taylor WR, et al. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). PLoS One. 2014;9(1):e85659.
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health Welfare. Cancer screening programs: quarterly data. Canberra: AIHW; 2022.
   Google Scholar
• Hong S, Shin HY, Lee B, et al. Increase in the colorectal cancer screening rate by a round-mailed fecal immunochemical testing kit and associated factors in underserved regions of Korea: a community-based Intervention study. Gut Liver. 2020;14(3):323–330.
   PubMed Web of Science ®Google Scholar
• Toes-Zoutendijk E, Portillo I, Hoeck S, et al. Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe. J Med Screen. 2020;27(2):68–76.
   PubMed Web of Science ®Google Scholar
• Weitzman ER, Zapka J, Estabrook B, et al. Risk and reluctance: understanding impediments to colorectal cancer screening. Preventive med. 2001;32(6):502–513.
   PubMed Web of Science ®Google Scholar
• Niedermaier T, Weigl K, Hoffmeister M, et al. Flexible sigmoidoscopy in colorectal cancer screening: implications of different colonoscopy referral strategies. Eur J Epidemiol. 2018;33(5):473–484.
   PubMed Web of Science ®Google Scholar
• Young GP, Symonds EL, Allison JE, et al. Advances in fecal occult blood tests: the FIT revolution. Dig Dis Sci. 2015;60(3):609–622.
   PubMed Web of Science ®Google Scholar
• Dolatkhah R, Dastgiri S, Jafarabadi MA, et al. Diagnostic accuracy of multitarget stool DNA testing for colorectal cancer screening: a systematic review and meta-analysis. Gastroenterol Hepatol. 2022;45(10):753–766.
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–1297.
   PubMed Web of Science ®Google Scholar
• Peng M, Chen C, Hulbert A, et al. Non-blood circulating tumor DNA detection in cancer. Oncotarget. 2017;8(40):69162–69173.
   PubMedGoogle Scholar
• Symonds EL, Young GP. Blood tests for colorectal cancer screening in the standard risk population. Current Colorectal Cancer Reports. 2015;11(6):397–407.
   Google Scholar
• Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014;14(1):183.
   PubMed Web of Science ®Google Scholar
• Osborne J, Wilson C, Moore V, et al. Sample preference for colorectal cancer screening tests: blood or stool? Open J Prev Med. 2012;2(3):326–331.
   Google Scholar
• Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane Handbook for systematic Reviews of interventions. Cochrane Database Syst Rev. 2019;10:Ed000142. doi: 10.1002/14651858.ED000142
   PubMed Web of Science ®Google Scholar
• Nagorni A, Bjelakovic G. Colonoscopic polypectomy for prevention of colorectal cancer. Cochrane Database Syst Rev. 2009;2. doi: 10.1002/14651858.CD007826
   Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
   PubMed Web of Science ®Google Scholar
• Lathlean TJH, Wassie MM, Winter JM, et al. Accuracy of blood-based biomarkers for screening precancerous colorectal lesions: a protocol for systematic review and meta-analysis. BMJ Open. 2022;12(5):e060712.
   PubMed Web of Science ®Google Scholar
• Yoon H, Shin CM, Park YS, et al. Total polyp number may be more important than size and histology of polyps for prediction of metachronous high-risk colorectal neoplasms. BMC Gastroenterol. 2022;22(1):91.
   PubMed Web of Science ®Google Scholar
• Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer. Am J Gastroenterol. 2017;112(7):1016–1030.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.
   PubMed Web of Science ®Google Scholar
• Reitsma JB, Rutjes A, Whiting P, et al. Chapter 9: assessing methodological quality. Cochrane Handbook For Systematic Reviews Of Diagnostic Test Accuracy. 2009;1.0.0:1–28.
   Google Scholar
• StataCorpStata Statistical Software: release 17. College Station (TX): StataCorp LLC; 2021.
   Google Scholar
• R Core Team. R :a language and environment for Statistical computing. 3.6.1 ed. Vienna Austria: R Foundation for Statistical Computing; 2019.
   Google Scholar
• Wickham H. ggplot2: elegant graphics for data analysis. (NY): Springer-Verlag; 2016.
   Google Scholar
• Ribbing Wilen H, Blom J, Hoijer J, et al. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives. Scand J Gastroenterol. 2019;54(3):303–310.
   PubMed Web of Science ®Google Scholar
• Syrek Jensen T, Chin J, Evans MA, et al. Screening for Colorectal Cancer - Blood-Based Biomarker Tests CAG-00454N). USA: Centers for Medicare & Medicaid Services; 2023. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=299
   Google Scholar
• Deeks JJ, HigginsJPT, Altman DG. Chapter 10: analysing data and undertaking meta-analyses Cochrane Handbook for Systematic Reviews of Interventions 6.4. In: Higgins JPT, Thomas J, Chandler J, et al, editors. Chichester (UK): John Wiley & Sons; 2022.
   Google Scholar
• Bujang MA, Adnan TH. Requirements for minimum sample size for sensitivity and specificity analysis. J Clin Diagn Res. 2016;10(1):YE01–YE06.
   PubMedGoogle Scholar
• Ding H, Lin J, Xu Z, et al. A global Evaluation of the performance indicators of colorectal cancer screening with fecal immunochemical tests and colonoscopy: a systematic review and meta-analysis. Cancers (Basel). 2022;14(4):1073.
   PubMed Web of Science ®Google Scholar
• Mai D, Zheng Y, Guo H, et al. Serum piRNA-54265 is a new biomarker for early detection and clinical surveillance of human colorectal cancer. Theranostics. 2020;10(19):8468–8478.
   PubMed Web of Science ®Google Scholar
• Chen H, Werner S, Butt J, et al. Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget. 2016;7(13):16420–16432.
   PubMedGoogle Scholar
• Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317–325. doi: 10.1136/gutjnl-2012-304149
   PubMed Web of Science ®Google Scholar
• Junca A, Tachon G, Evrard C, et al. Detection of colorectal cancer and advanced adenoma by liquid biopsy (decalib study): the ddPCR challenge. Cancers (Basel). 2020;12(6):1482.
   PubMed Web of Science ®Google Scholar
• Lim DH, Lee JH, Kim JW. Feasibility of CYFRA 21-1 as a serum biomarker for the detection of colorectal adenoma and advanced colorectal adenoma in people over the age of 45. J Clin Lab Anal. 2018;32(1):e22163. doi: 10.1002/jcla.22163
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhao G, Miao J, et al. Performance comparison between plasma and stool methylated SEPT9 tests for detecting colorectal cancer. Front Genet. 2020;11:324. doi: 10.3389/fgene.2020.00324
   PubMed Web of Science ®Google Scholar
• Ørntoft MB, Nielsen HJ, Ørntoft TF, et al. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study. BMC Cancer. 2015;15:819.
   PubMed Web of Science ®Google Scholar
• Otero-Estévez O, De Chiara L, Rodríguez-Girondo M, et al. Serum matrix metalloproteinase-9 in colorectal cancer family-risk population screening. Sci Rep. 2015;5(1):13030.
   PubMedGoogle Scholar
• Pedersen SK, Symonds EL, Baker RT, et al. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer. 2015;15(1):654.
   PubMedGoogle Scholar
• Symonds EL, Pedersen SK, Baker RT, et al. A blood test for methylated BCAT1 and IKZF1 vs. A fecal immunochemical test for detection of colorectal neoplasia. Clin Transl Gastroenterol. 2016;7(1):e137.
   PubMed Web of Science ®Google Scholar
• Tao S, Haug U, Kuhn K, et al. Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. Br J Cancer. 2012;106(8):1424–1430.
   PubMed Web of Science ®Google Scholar
• Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011;9(1):133.
   PubMedGoogle Scholar
• Werner S, Krause F, Rolny V, et al. Evaluation of a 5-marker blood test for colorectal cancer early detection in a colorectal cancer screening setting. Clin Cancer Res. 2016;22(7):1725–1733.
   PubMed Web of Science ®Google Scholar
• Wild N, Andres H, Rollinger W, et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010;16(24):6111–6121.
   PubMed Web of Science ®Google Scholar
• Young GP, Symonds EL, Nielsen HJ, et al. Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer. Clin Epigenetics. 2021;13(1):14.
   PubMed Web of Science ®Google Scholar
• Zhang G, He F, Zhao G, et al. Combining serum DNA methylation biomarkers and Protein tumor markers improved Clinical sensitivity for early detection of colorectal cancer. Int J Genomics. 2021;2021:6613987.
   PubMed Web of Science ®Google Scholar
• Hosono Y, Goto M, Kobayashi D, et al. Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma. Mol Clin Oncol. 2015;3(3):595–600.
   PubMedGoogle Scholar
• Ciarloni L, Ehrensberger SH, Imaizumi N, et al. Development and Clinical validation of a blood test based on 29-gene expression for early detection of colorectal cancer. Clin Cancer Res. 2016;22(18):4604–4611.
   PubMed Web of Science ®Google Scholar
• Ciarloni L, Hosseinian S, Monnier-Benoit S, et al. Discovery of a 29-gene panel in peripheral blood mononuclear cells for the detection of colorectal cancer and adenomas using high throughput real-time PCR. PLoS One. 2015;10(4):e0123904.
   PubMed Web of Science ®Google Scholar
• Tänzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One. 2010;5(2):e9061.
   PubMed Web of Science ®Google Scholar
• Herreros-Villanueva M, Duran-Sanchon S, Martín AC, et al. Plasma MicroRNA signature validation for early detection of colorectal cancer. Clin Transl Gastroenterol. 2019;10(1):e00003.
   PubMedGoogle Scholar
• Zhao G, Ma Y, Li H, et al. A novel plasma based early colorectal cancer screening assay base on methylated SDC2 and SFRP2. Clin Chim Acta. 2020;503:84–89. doi: 10.1016/j.cca.2020.01.010
   PubMed Web of Science ®Google Scholar
• Scimia M, Du J, Pepe F, et al. Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study. J Clin Pathol. 2018;71(12):1123–1126.
   PubMed Web of Science ®Google Scholar
• Rasmussen L, Nielsen HJ, Christensen IJ. Early detection and recurrence of colorectal adenomas by combination of eight cancer-associated biomarkers in plasma. Clin Exp Gastroenterol 2020;13: 273–284. doi: 10.2147/CEG.S251633
   PubMed Web of Science ®Google Scholar
• Otero-Estévez O, De Chiara L, Rodríguez-Berrocal FJ et al. Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test. Br J Cancer. 2015;112(2):375–381.
   PubMed Web of Science ®Google Scholar
• De Chiara L, Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, et al. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer. 2010;10(1):333.
   PubMedGoogle Scholar
• Jeun M, Lee HJ, Park S, et al. A novel blood-based colorectal cancer diagnostic technology using electrical detection of colon cancer secreted Protein-2. Adv Sci. 2019;6(11):1802115.
   Web of Science ®Google Scholar
• Wu X, Zhang Y, Hu T, et al. A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer. Mol Oncol. 2021;15(10):2702–2714.
   PubMed Web of Science ®Google Scholar
• Pulverer W, Kruusmaa K, Schönthaler S, et al. Multiplexed DNA methylation analysis in colorectal cancer using liquid biopsy and its diagnostic and predictive value. Curr Issues Mol Biol. 2021;43(3):1419–1435.
   PubMed Web of Science ®Google Scholar
• Lin K. mSEPT9 blood test (Epi proColon) for colorectal cancer screening. Am Fam Physician. 2019;100:10–11.
   PubMed Web of Science ®Google Scholar
• Song L, Peng X, Li Y, et al. The SEPT9 gene methylation assay is capable of detecting colorectal adenoma in opportunistic screening. Epigenomics. 2017;9(5):599–610.
   PubMed Web of Science ®Google Scholar
• Marcuello M, Duran-Sanchon S, Moreno L, et al. Analysis of a 6-mirna signature in serum from colorectal cancer screening participants as non-invasive biomarkers for advanced adenoma and colorectal cancer detection. Cancers (Basel). 2019;11(10):1542.
   PubMed Web of Science ®Google Scholar
• Giráldez MD, Lozano JJ, Ramírez G, et al. Circulating microRnas as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol. 2013;11(6):681–8.e3. doi: 10.1016/j.cgh.2012.12.009
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–859.
   PubMedGoogle Scholar
• Moshayoff V, Faktor O, Laghi L, et al. Feasibility of unbiased RNA profiling of colorectal tumors: a proof of principle. PLoS One. 2016;11(7):e0159522.
   PubMed Web of Science ®Google Scholar
• Wong SC, Ng SS, Cheung MT, et al. Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. Br J Cancer. 2011;104(6):1000–1006.
   PubMed Web of Science ®Google Scholar
• Tsai WS, You JF, Hung HY, et al. Novel circulating tumor cell assay for detection of colorectal adenomas and cancer. Clin Transl Gastroenterol. 2019;10(10):e00088.
   PubMed Web of Science ®Google Scholar
• Perrone F, Lampis A, Bertan C, et al. Circulating free DNA in a screening program for early colorectal cancer detection. Tumori. 2014;100(2):115–121.
   PubMed Web of Science ®Google Scholar
• Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Ther. 2016;1(1):15004.
   PubMedGoogle Scholar
• Shah V, Shah J. Recent trends in targeting miRnas for cancer therapy. J Pharm Pharmacol. 2020;72(12):1732–1749. doi: 10.1111/jphp.13351
   PubMed Web of Science ®Google Scholar
• Yamada A, Cox MA, Gaffney KA, et al. Technical factors involved in the measurement of circulating MicroRNA biomarkers for the detection of colorectal neoplasia. PLoS One. 2014;9(11):e112481. :
   PubMed Web of Science ®Google Scholar
• McDonald J, Milosevic D, Reddi H, et al. Analysis of circulating MicroRNA: preanalytical and analytical challenges. Clin Chem. 2011;57(6):833–840.
   PubMed Web of Science ®Google Scholar
• Kirschner MB, Edelman JJ, Kao SC, et al. The impact of hemolysis on cell-free microRNA biomarkers. Front Genet. 2013;4:94.
   PubMedGoogle Scholar
• Tóth K, Wasserkort R, Sipos F, et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS One. 2014;9(12):e115415.
   PubMed Web of Science ®Google Scholar
• Ahlquist DA. Multi-target stool DNA test: a new high bar for noninvasive screening. Dig Dis Sci. 2015;60(3):623–33.
   PubMed Web of Science ®Google Scholar
• Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2015;30(5):830–833.
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.
   PubMed Web of Science ®Google Scholar
• Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016;7(30):48832–48841. doi: 10.18632/oncotarget.9453
   PubMedGoogle Scholar
• van der Vaart M, Pretorius PJ. The origin of circulating free DNA. Clin Chem. 2007;53(12):2215–2215. doi: 10.1373/clinchem.2007.092734
   PubMed Web of Science ®Google Scholar
• Tóth K, Á V P, Kalmár A, et al. Circadian rhythm of methylated septin 9, cell-free DNA amount and tumor markers in colorectal cancer patients. Pathol Oncol Res. 2017;23(3):699–706.
   PubMed Web of Science ®Google Scholar
• Alese OB, Cook N, Ortega-Franco A, et al. Circulating tumor DNA: an emerging tool in gastrointestinal cancers. Am Soc Clin Oncol Educ Book. 2022;2022(42):279–298.
   Google Scholar
• Keller L, Belloum Y, Wikman H, et al. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124(2):345–358.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 4.2021. Fort Washington, PA: National-Comprehensive-Cancer-Network (NCCN); 2021.
   Google Scholar
• Lee PB, Gilmore A. Cancer Council Australia colorectal cancer guidelines working party. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Volume 2023. Sydney: Cancer Council Australia; 2017.
   Google Scholar
• Leung WK, Shin VY, Law WL. Detection of methylated septin 9 DNA in blood for diagnosis, prognosis, and surveillance of colorectal cancer. Hong Kong Med J. 2019;9(25 Suppl):32–34.
   Google Scholar
• Thomas DS, Fourkala EO, Apostolidou S, et al. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer. 2015;113(2):268–274.
   PubMed Web of Science ®Google Scholar
• Su BB, Shi H, Wan J. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol. 2012;18:2121–6.
   PubMed Web of Science ®Google Scholar
• Cutait R, Alves VA, Lopes LC, et al. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum. 1991;34:917–20.
   PubMed Web of Science ®Google Scholar
• Gold P, Shuster J, Freedman SO. Carcinoembryonic antigen (CEA) in clinical medicine: historical perspectives, pitfalls and projections. Cancer. 1978;42:1399–405.
   PubMed Web of Science ®Google Scholar
• Thomas P, Zamcheck N. Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA). Dig Dis Sci. 1983;28(3):216–224. doi: 10.1007/BF01295116
   PubMed Web of Science ®Google Scholar
• Lawler M, Johnston B, Van Schaeybroeck S, et al. 74 - Colorectal Cancer. In: Niederhuber J, Armitage J, Kastan M, Doroshow J Tepper J, editors. Abeloff’s clinical oncology Sixth ed. Philadelphia:Elsevier; 2020. p. 1219–1280.e15.
   Google Scholar
• Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–2272.
   PubMed Web of Science ®Google Scholar
• Zauber P, Marotta S, Sabbath-Solitare M. KRAS gene mutations are more common in colorectal villous adenomas and in situ carcinomas than in carcinomas. Int J Mol Epidemiol Genet. 2013;4(1):1–10.
   PubMedGoogle Scholar
• Yang HM, Mitchell JM, Sepulveda JL, et al. Molecular and histologic considerations in the assessment of serrated polyps. Arch Pathol Lab Med. 2015;139(6):730–741.
   PubMed Web of Science ®Google Scholar
• Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008;130(6):1091–1103.
   PubMed Web of Science ®Google Scholar
• Tsai FC, Strum WB. Prevalence of advanced adenomas in small and diminutive colon polyps using direct measurement of size. Dig Dis Sci. 2011;56(8):2384–2388. doi: 10.1007/s10620-011-1598-x
   PubMed Web of Science ®Google Scholar
• Young GP, Senore C, Mandel JS, et al. Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer. Cancer. 2016;122(6):826–839. doi: 10.1002/cncr.29865
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Senore C, Young GP, et al. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles. Gut. 2023;72(10):1904–1918.
   PubMed Web of Science ®Google Scholar
• Otero-Estévez O, Gallardo-Gomez M, Cadena MP, et al. Value of serum NEUROG1 methylation for the detection of advanced adenomas and colorectal cancer. Diagnostics. 2020;10(7):437.
   Web of Science ®Google Scholar
• Suehiro Y, Hashimoto S, Higaki S, et al. Blood free-circulating DNA testing by highly sensitive methylation assay to diagnose colorectal neoplasias. Oncotarget. 2018;9(24):16974–16987.
   PubMedGoogle Scholar
• Otero-Estévez O, De Chiara L, Barcia-Castro L, et al. Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer. Sci Rep. 2016;6(1):26703.
   PubMedGoogle Scholar
• Niedermaier T, Weigl K, Hoffmeister M, et al. Diagnostic performance of flexible sigmoidoscopy combined with fecal immunochemical test in colorectal cancer screening: meta-analysis and modeling. Eur J Epidemiol. 2017;32(6):481–493.
   PubMed Web of Science ®Google Scholar
• Chung S. False-positive elevations in carcinoembryonic antigen levels at a Health screening center. Laboratory Medicine Online. 2019;9(3):146–152. lmo. doi: 10.3343/lmo.2019.9.3.146
   Google Scholar
• Weber TH, Kerttula Y. Carcinoembryonic Antigen (CEA) in Blood in Cases of Pneumonia. Scand J Infect Dis. 1986;18(6):547–550. doi: 10.3109/00365548609021660
   PubMed Web of Science ®Google Scholar
• Johansson Å, Enroth S, Gyllensten U, et al. Continuous aging of the human DNA methylome throughout the human lifespan. PLoS One. 2013;8(6):e67378. doi: 10.1371/journal.pone.0067378
   PubMed Web of Science ®Google Scholar
• Field AE, Robertson NA, Wang T, et al. DNA methylation clocks in aging: categories, causes, and consequences. Molecular Cell. 2018;71(6):882–895.
   PubMed Web of Science ®Google Scholar
• Powrozek T, Krawczyk P, Kucharczyk T, et al. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol. 2014;31(4):917.
   PubMed Web of Science ®Google Scholar
• Høydahl Ø, Edna T-H, Xanthoulis A, et al. Long-term trends in colorectal cancer: incidence, localization, and presentation. BMC Cancer. 2020;20(1):1077.
   PubMed Web of Science ®Google Scholar
• De Palma FDE, D’Argenio V, Pol J, et al. The molecular hallmarks of the serrated pathway in colorectal cancer. Cancers. 2019;11(7):1017.
   PubMed Web of Science ®Google Scholar
• Symonds EL, Cock C, Meng R, et al. Uptake of a colorectal cancer screening blood test in people with elevated risk for cancer who cannot or will not complete a faecal occult blood test. Eur J Cancer Prev. 2018;27(5):425–432. doi: 10.1097/CEJ.0000000000000352
   PubMed Web of Science ®Google Scholar
• Gupta S, Miller S, Koch M, et al. Financial incentives for promoting colorectal cancer screening: a randomized, comparative effectiveness trial. Am J Gastroenterol. 2016;111(11):1630–1636.
   PubMed Web of Science ®Google Scholar
• Aujoulat P, Le Goff D, Dany A, et al. Improvement of participation rate in colorectal cancer (CRC) screening by training general practitioners in motivational interviewing (AmDepccr). Trials. 2022;23(1):144.
   PubMed Web of Science ®Google Scholar
• Ioannou S, Sutherland K, Sussman DA, et al. Increasing uptake of colon cancer screening in a medically underserved population with the addition of blood-based testing. BMC Cancer. 2021;21(1):966.
   PubMed Web of Science ®Google Scholar
• Ladabaum U, Allen J, Wandell M, et al. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. Cancer Epidemiol Biomarkers Prev. 2013;22(9):1567–1576.
   PubMed Web of Science ®Google Scholar
• Peterse EFP, Meester RGS, de Jonge L, et al. Comparing the cost-effectiveness of innovative colorectal cancer screening tests. JNCI. 2020;113(2):154–161.
   Google Scholar
• Roth JA, deVos T, Ramsey SD. Clinical and budget impact of increasing colorectal cancer screening by blood- and stool-based testing. Am Health Drug Benefits. 2019;12(5):256–262.
   PubMed Web of Science ®Google Scholar
• Lansdorp-Vogelaar I, Goede SL, Bosch LJW, et al. Cost-effectiveness of high-performance biomarker tests vs fecal immunochemical test for noninvasive colorectal cancer screening. Clin Gastroenterol Hepatol. 2018;16(4):504–512.e11.
   PubMed Web of Science ®Google Scholar
• Aravanis AM, Lee M, Klausner RD. Next-generation sequencing of circulating tumor DNA for early cancer detection. Cell. 2017;168(4):571–574. doi: 10.1016/j.cell.2017.01.030
   PubMed Web of Science ®Google Scholar
• Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–930.
   PubMed Web of Science ®Google Scholar
• Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167–1177.
   PubMed Web of Science ®Google Scholar
• Spychalski P, Kobiela J, Wieszczy P, et al. Adenoma to colorectal cancer estimated transition rates stratified by BMI categories-A cross-sectional analysis of asymptomatic individuals from screening colonoscopy program. Cancers (Basel). 2021;14(1):62.
   PubMed Web of Science ®Google Scholar
• Bhardwaj M, Gies A, Weigl K, et al. Evaluation and validation of plasma proteins using two different Protein detection methods for early detection of colorectal cancer. Cancers (Basel). 2019;11(10):1426.
   PubMed Web of Science ®Google Scholar
• Chen H, Qian J, Werner S, et al. Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer. Clin Epidemiol. 2017;9:517–526.
   PubMed Web of Science ®Google Scholar
• Ahlquist DA, Taylor WR, Mahoney DW, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol. 2012;10(3):272–7.e1.
   PubMed Web of Science ®Google Scholar